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This study is a retrospective cohort analysis of patients undergoing two different
treatment modalities (brachytherapy and endoresection) for medium sized choroidal
melanoma. Study methods involve the collection of baseline and follow-up data
from three sources: 1) A database collected by the department of Radiation
Oncology at Groote Schuur Hospital; 2) Private physicians responsible for patient 
follow-up following brachytherapy; 3) Private physicians responsible for
endoresection surgery and patient follow-up. To date there has been limited
publication of the outcomes of patients treated for choroidal melanoma in South
Africa. The study aims to compare the outcomes of these procedures to help identify
the possible benefits of each form of treatment.
Literature search: 
The literature review reveals a paucity of comparative studies of these treatment
methods. Most publications are case series and meta-analyses. Useful comparative
information can be obtained from the Collaborative Ocular Melanoma Study which
was designed to compare conservative (eye preserving) treatment with enucleation
(removal of the eye). The outcome of patients treated with brachytherapy in this
study is a useful reference but no comparison was made with other forms of












We found that brachytherapy had 4.2 times increased risk of poor visual outcomes 
compared to endoresection. Mean visual acuity of eyes with vision better than 
perception of light (PL) was similar between the groups and approximately 40% of 
each group had good visual outcomes. The tumours that underwent endoresection 
were taller and further from the fovea than those receiving brachytherapy which 
may represent a selection bias. The numbers in the endoresection group were also 
small which limited the power of the study. Predictors of poor vision, recurrence 




Data quality and loss to follow-up are discussed separately. In addition it was noted 
during the study that patients treated with brachytherapy prior to 1st May 1994 
received sub therapeutic doses of radiation. These patients were analysed as a group 
and revealed significantly poorer outcomes compared to those treated with 
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PART A: PROTOCOL 
Title: 
Brachytherapy and Endoresection in the Treatment of Choroidal Melanoma. 
A review of patients treated in South Africa 
 
Summary: 
This retrospective cohort study aims to assess the outcomes of patients with 
medium sized choroidal melanomas treated with brachytherapy or endoresection 
and to make comparison of the outcomes following these treatments.  
 
Data to be obtained from three sources:  
1) Pre-operative patient and tumour characteristics collected by the 
department of Radiation Oncology at Groote Schuur Hospital. 
2) Follow-up data from private physicians responsible for patient follow-up 
following brachytherapy. 
3) Pre- and post-operative data from private physicians responsible for 
endoresection surgery and patient follow-up. 
 
Pre-operative data include age, gender, date of diagnosis, left or right eye, pre-
operative visual acuity, presence of other non-associated pathology and type and 
date of the procedure performed.  
 
Documented pre-operative tumour characteristics include height (thickness), largest 











eye (predominant quadrant), and the presence or absence of an associated 
exudative retinal detachment. 
Outcomes to be measured are duration of follow-up, final best corrected visual 
acuity and complications related to the tumour or treatment, particularly: 1) 
Recurrence of the tumour and date of recurrence; 2) Enucleation and the date and 
reason for enucleation; 3) Date of diagnosis of metastases or death from any cause.  
Rates of tumour recurrence, enucleation and metastases will be calculated for each
treatment group. Survival type analysis will be performed on both treatment groups 
with events being recurrence, enucleation and metastases or death from any cause. 
Comparison of treatment outcomes between the two treatment groups will be
made. Risk factors of interest will be analysed in logistic regression and Cox
proportional hazards models to determine possible predictors of outcomes.
Rationale: 
Uveal melanoma is a rare condition that is managed in selected specialist centres.
Groote Schuur Hospital is the only centre in South Africa to provide brachytherapy 
for the treatment of uveal melanoma. Patients are referred for treatment from
private and public facilities throughout the country.
A database of patients undergoing brachytherapy for choroidal melanoma has been 
collected by the department of Radiation Oncology since 1974. This database is 












To date only a small series of 21 patients was published in 19921. It is the intention 
of this study to examine the outcomes of all patients with medium sized melanoma 
treated at this facility with brachytherapy. These outcomes will be compared to a 
national cohort of patients undergoing alternative treatment, namely endoresection.  
 
Endoresection is a technically challenging surgical treatment for choroidal 
melanoma. It is performed by experienced vitreoretinal surgeons and the numbers in 
published series are small. The relatively small number of surgeons performing the 
procedure provides opportunity to gather data representative of the national 
experience of this form of treatment. This study will therefore provide a useful 
analysis and comparison of outcomes of the major forms of treatment used in South 
Africa for the management of choroidal melanoma. At present there are no similar 
studies from South Africa. 
 
Objectives: 
This study aims to assess the following outcomes of brachytherapy and 
endoresection in the treatment of uveal melanoma: final best corrected visual 
acuity; local tumour recurrence rate and time to recurrence; enucleation rate 
(removal of the eye) and time to enucleation; rate of metastases or death and time 
to diagnosis of metastases or death from any cause. Further analysis will explore 

















This is a retrospective cohort study of two groups of participants, one undergoing 




Brachytherapy group: All participants undergoing brachytherapy for this condition in 
South Africa have been treated at Groote Schuur Hospital or a nearby private facility 
with the use of a radioactive plaque supplied by Groote Schuur Hospital. A database 
was established in 1974 and will provide a list of consecutive participants who have 
undergone this procedure. As this form of treatment is most suitable for small or 
medium sized melanomas and most internationally published literature examines 
the outcomes of brachytherapy for medium sized tumours, participants with large 
tumours will be excluded from the analysis.  
 
Endoresection group: Endoresections are performed by a select group of vitreo-
retinal surgeons in the country. All members of the South African Vitreo-Retinal 
Society (SAVRS) will be contacted via the society email list inviting participation in 
the study (see Appendix B). Specific email notification will be sent to all surgeons 
with known experience in this procedure informing them of the proposed data 
collection and requesting their contribution to the database. More anterior tumours 
and large tumours are less amenable to endoresection and will be excluded from 












endoresections. Participants who have had prior treatment to the tumour and had a 




Brachytherapy is a form of radiation therapy applied via a custom made gold plaque 
inlayed with Iodine-125 radio-active seeds. Precise measurements of the size and 
location of the tumour are determined by a specialist ophthalmologist with 
particular reference to basal diameters and height (thickness) of the tumour, and its 
location within the eye with reference to the optic disc, fovea and limbus (sclera-
corneal junction).   
 
Manufacture of the plaque is overseen by a nuclear physicist in the department of 
Radiation Oncology at Groote Schuur Hospital. The plaque is sutured to the sclera 
overlying the tumour and remains in place for up to 5 days to achieve a therapeutic 
dose of 80-100Gy to the apex of the lesion.  
 
Endoresection 
Endoresection is a surgical procedure in which the tumour is excised from the inner 
surface of the eye. The procedure is technically challenging and carries risk of 
significant complications. The eye is usually filled with silicone oil at the end of the 
procedure which remains for a period of at least 3 months to allow for stabilisation 
and healing of the surgical site. The risk of intra-operative complications is higher 













Baseline observations will include age, gender, date of diagnosis, left or right eye, 
pre-operative visual acuity, presence of other non-associated pathology and type 
and date of the procedure performed. Pre-operative tumour characteristics to be 
measured are height (thickness), largest basal diameter, distance from the optic disc, 
fovea and limbus, location within the eye (predominant quadrant), and the presence 
or absence of an associated exudative retinal detachment. 
 
Follow-up data: 
The most recent follow-up data available will be obtained on all participants. Follow-
up of brachytherapy patients treated at our facility is performed by the referring 
ophthalmologist. Six monthly follow-up data are requested routinely from these 
ophthalmologists. If these updates are not available in the patient folder then it will 
be obtained from the referring practice by telephone and will be reliant upon 
accurate records being kept by the referring ophthalmologist.  
 
In the case of endoresections, all baseline and follow-up data will be requested from 
the surgeon who performed endoresection.  
 
Follow-up data will include best corrected final visual acuity and complications 
related to the tumour or treatment, namely: 1) Recurrence of the tumour and date 
of recurrence; 2) Enucleation of the eye and the date and reason for enucleation; 3) 
Date of metastases or death from metastases or any cause. Because Groote Schuur 












recurrence are discussed with specialists at this facility. This is likely to improve the 
accuracy of diagnosis of tumour recurrence. 
 
Visual acuity may be recorded in different ways. Commonly used methods are 
Snellen acuity or decimal acuity. There are limitations to the use of these measures 
as they do not always give a good measure of overall visual function. Other measures 
of visual function are, however, not commonly measured in these patients. Snellen 
acuity and decimal acuity are not amenable to statistical analysis and will therefore 
be converted to logarithm of the minimal angle of resolution (LogMAR acuity) for 
analysis2. Visual measure of perception of light (PL) and no perception of light (NPL) 
are not truly measures of visual acuity but perception of a sensory stimulus and are 
not included in this scale 2. 
 
Below is a table relating different visual acuity measures: 
 
 
   
  Table 1: Different visual acuity measures  
Snellen equivalent Decimal equivalent LogMAR equivalent 
6/6 1.00 0.00 
6/12 0.50 0.30 
6/18.9 0.32 0.50 
6/37.5 0.16 0.80 
6/60 0.10 1.00 
Count Fingers (CF) 0.01 2.00 












Recurrence of tumour growth is made on the basis of clinical examination and 
ultrasound measurements with comparison made with previous photographs and 
tumour dimensions. If an eye is enucleated it is possible to analyse the tumour 
histologically to confirm tumour recurrence. 
Diagnosis of metastases is usually made with a combination of liver function testing,
ultrasound of the liver and chest X-ray and confirmed by an oncologist. Screening
investigations are usually performed six monthly in all patients that have been
diagnosed with a uveal melanoma.
Sample size 
Endoresection is an uncommon, technically difficult form of treatment. We
anticipate that numbers of participants receiving this treatment will be considerably
fewer than those in the brachytherapy group. This may limit the power of statistical
analysis to demonstrate differences in treatment outcomes.
Data management and analysis
Data will be collected in a Microsoft Excel® database. Blank copies of the database 
will be emailed to all surgeons performing endoresection. Completed lists will be 
returned via email to Dr James Rice at james.rice@uct.ac.za who will collate and 












STATA 11.0 (StataCorp. LP, USA) will be used to perform analysis. Mean and median 
outcomes will be used for normally and non-normally distributed data respectively 
except for mean of visual acuity and distances measured within the eye.   
 
Visual acuity will be analysed in LogMAR format. As Perception of Light (PL) and No 
Perception of Light (NPL) are not measures of visual acuity but rather detection of a 
stimulus, they cannot be included in analysis of LogMAR acuities. Visual outcomes 
will therefore also be analysed categorically as follows: 
 
1) Normal or mild visual impairment (6/5 to 6/18) (LogMAR -0.08 to 0.48) 
2) Moderate visual impairment (6/24 to 6/48) (LogMAR 0.60 to 0.90) 
3) Severe visual impairment (6/60 to 3/60) (LogMAR 1.00 to 1.30) 
4) Profound visual impairment or blindness: 2/60 or worse (LogMAR 1.48 or 
worse) 
 
PL and NPL vision will be ascribed a LogMAR value of 5 so as to be included in the 
blindness group for count purposes but will be omitted when determining the 
average visual acuity. 
 
Risk factors for poor visual outcome will be examined in a logistic regression model 
using category 4 (profound visual impairment or blindness) as a dichotomous 
outcome variable. Presenting visual acuity and the type of treatment will be included 












Survival type analysis will be performed on both treatment groups with events being 
recurrence, enucleation and metastases or death from all causes. Statistical 
comparison of survival curves will be made. 
Risk factors of interest will be analysed in Cox proportional hazards models to 
determine their possible association with the outcomes. Regression model building 
will use Likelihood ratio tests and Aikaides information criteria (AIC) to determine 
the best model starting with a baseline of possible confounders. 
Ethics
Ethical approval for this study will be obtained from the University of Cape Town
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Uveal melanoma is the most common primary intraocular malignancy in adults. The 
tumour is more common in Caucasians, with an overall incidence of 5-7 per million 
per year 1, 2. Known associations include ocular and oculodermal melanocytosis and 
other uncommon systemic conditions including neurofibromatosis type 1 3, 4. 
 
The tumour arises from the pigmented cells of the uvea which is anatomically 
divided into the iris, ciliary body and choroid. This study will involve participants with 
choroidal melanoma only. Tumours can be classified according to size into small 
medium and large. 
  Table 1: Classification of tumour size for the purpose of this study 
  (varies slightly between studies)13 
 
 Height (thickness) Largest basal diameter 
Small < 2.5mm  
Medium 2.5-10mm ≤ 16mm 
Large > 10mm > 16mm 
 
 
Objectives of literature review 
This review explores published outcomes related to the management of choroidal 
melanoma with brachytherapy and endoresection. Of interest are final visual acuity 
and rates of tumour recurrence, enucleation and metastases. Time to these events 
and risk factors for poorer outcomes are examined in the literature. 
 












A Medline search was performed using key words ‘choroidal melanoma’, 
‘brachytherapy’, ‘plaque therapy’, ‘radiotherapy’, ‘endoresection’. Outcomes of the 
treatment of large tumours and outcomes following secondary endoresections have 
not been reviewed. 
 
Quality of included studies 
Because choroidal melanoma is an uncommon condition many publications are case 
series. Most series are less than 100 participants5-8 treated with brachytherapy and 
even fewer treated with endoresection with the largest series of 41 participants 
undergoing primary endoresection7, 9-12. The small numbers in these series and the 
non-randomised nature of the studies make it difficult to draw conclusions about 
different treatment options. Shields and Shields et al13 published visual outcomes of 
a large series of 1106 consecutive cases of plaque therapy patients and explored the 
risk factors for poorer outcomes using Cox proportional hazards regression models. 
The larger number in this series increases the precision of estimates. Meta-
analyses14, 15 have combined studies to increase sample size and study power. 
 
The Collaborative Ocular Melanoma Study (COMS)16-18 was a randomised trial 
involving 43 centres across the United States and Canada and recruited participants 
from 1986 to 1998. Six resource centres had roles in quality assurance of the study. 
1317 participants were enrolled in the medium tumour trial and participants were 
followed for up to 15 years. This study was designed to overcome the challenges of 
studying an uncommon condition and enough participants could be recruited 












determine whether conservative (i.e. eye preserving) treatment with brachytherapy 
for medium sized tumours reduced survival compared to enucleation (eye removal). 
The outcome of the brachytherapy arm of this study is useful for comparison with 
other studies, including ours. 
 
Treatment options for choroidal melanoma 
A variety of treatment options are available for the management of choroidal 
melanoma. More radical treatment involves removal of the eye (enucleation) which 
was the treatment of choice until more modern techniques became available. 
Enucleation is still necessary when a lesion is too large to treat, has caused extensive 
damage, or if other forms of treatment are unsuccessful.  
 
Modern forms of treatment aim to conserve the eye. These include plaque 
brachytherapy (Ruthenium-106, Iodine-125 and Strontium-90), proton beam 
irradiation and trans-pupillary thermotherapy (TTT). Ruthenium-106 emits electrons 
and is used to treat tumours up to 5mm in thickness. It has a long half life of 368 
days making it possible to use the same plaques for many patients. Iodine-125 emits 
gamma radiation and is able to treat thicker tumours (up to 10mm). Its half life is 
about 60 days. While Ruthenium-106 plaques come in premade sizes, Ioding-125 
plaques are custom made for the individual tumour.  
 
Surgical excision is possible and can be performed trans-scleral (from the outside of 
the eye)19  or trans-vitreal (from the inside of the eye) 9, 12, 20. Trans-vitreal excision is 












for example plaque radiotherapy combined with TTT or endoresection combined 
with plaque radiotherapy or TTT.  
 
One aim of the COMS was to determine whether conservative treatment increased 
the risk of metastases and death compared with enucleation. The Medium Tumour 
Trial component of this study showed that all cause mortality rates following Iodine-
125 brachytherapy did not differ from mortality rates following enucleation for up to 
12 years after treatment 21.  
 
Brachytherapy outcomes 
1) Visual loss 
Visual loss following brachytherapy is common during the first five years after 
treatment 22. In the COMS, regardless of baseline visual acuity, the five year 
cumulative rate for visual acuity of LogMAR 1.00 or worse was 63% (CI, 59%-68%); 
for visual acuity of LogMAR 1.60 or worse, the rate was 45% (CI,41%-50%). Sia and 
Harper et al6 found no correlation between visual outcome and tumour size or 
location but others suggest that retention of vision may be more likely if the tumour 
is more than 3 mm from the optic disc and fovea and if the vision is good at 
presentation 7. 
 
In a review of 1300 consecutive patients treated with brachytherapy 13, 1106 had 
visual acuity of LogMAR 0.70 or better at the time of treatment. In this group poor 
visual acuity (LogMAR 1.00 or greater) was found in 34% at 5 years and 68% at 10 











ultimate poor visual acuity of LogMAR 1.00 or worse was found in 24% with small 
tumours (<3.0mm thick), 30% with medium tumours (3.1-8.0mm), and 64% with
larger tumours (>8.0mm). Tumours less than 5 mm from the optic disc or fovea 
demonstrated poor visual acuity in 35% at 5 years, whereas those 5mm or more
from the optic disc and fovea showed poor visual acuity in 25% at 5 years. Van
Ginderdeuren and Van Limbergen et al23 suggest that Strontium-90 treatment may
result in better visual outcomes. The most common causes of visual loss following
brachytherapy are radiation maculopathy and cataract.35 By 5 years after
brachytherapy 83% of COMS participants had developed cataract. The most common
cause of failure of vision to improve after cataract surgery was the presence of
radiation maculopathy.
Management of radiation maculopathy has included laser photocoagulation,
photodynamic therapy, intravitreal steroids and, more recently, intravitreal anti-
vascular endothelial growth factor (anti-VEGF) treatments. Stability or improvement
of visual acuity may be achieved in approximately 50% of cases. Central macular
thickness has been shown to improve although the effects may only be short-lived
and the benefits in those with longstanding macular oedema are less clear.36
In addition, plaque designs are being improved to provide a more ‘collimated’ 
radiation to reduce collateral retinal injury.36 












In the COMS the treatment failure rate (tumour growth, recurrence or extra-scleral 
extension) was 10.3% (CI, 8.0%-13.2%) at 5 years24. Treatment was more likely to fail 
with increasing patient age, increase in tumour thickness and more posterior 
location. Similarly, an 8% failure rate at 5 years was found in a study with Strontium-
9023. Other studies by Sia and Harper et al6 and Krohn and Monge et al8 with up to 3 
years follow-up have found local failure between 3.6% and 14.3% 
 
3) Globe retention (enucleation) 
Enucleation rates vary across studies. In a study of 49 eyes by Sia and Harper et al6 
the all cause enucleation rate was 24.5% over 39.5 months. In contrast, by five years 
12.5% (CI, 10.0%-15.6%) of the COMS patients required enucleation24. Failure to 
control the growth of the lesion was a more common cause of early enucleation 
whereas pain was more likely to cause patients to undergo enucleation beyond three 
years. The COMS found that risk for enucleation was increased with increasing 
thickness of the lesion, a more posterior location of the posterior tumour edge and 
poor presenting visual acuity.  
 
Other studies suggest that between 5% and 10% of patients treated with 
brachytherapy ultimately require enucleation24-26. Retention of the eye may be more 
likely if the tumour is less than 16mm in diameter, less than 6mm thick and more 
than 3mm from the disc and fovea 7. 
 
 












Metastatic spread of ocular melanoma is haematogenous and the most common 
organ involved is the liver. Once systemic spread occurs, prognosis is normally poor 
with the median time from diagnosis of metastases to death of less than 6 months27.  
 
The five year metastasis rate for histologically confirmed melanoma  was 10% in the 
plaque treatment arm of the COMS Medium Tumour Trial17. The adjusted estimate 
for 5 year survival was 82%14, 21.  
 
A meta-analysis of 1066 patients treated with Ruthenium plaque therapy found a 5-
year melanoma related mortality of 6% for small / medium tumours and 26% for 
large tumours 14.  
 
Five year survival following brachytherapy appears to lie between 80 and 90%6, 23 
although smaller series have found higher 5 year mortality28. A recent systematic 
review2 of 4070 patients with primary uveal melanoma found an 81.6% five year 
survival which is similar to the range of 77% to 84% reported by Singh and Topham15 
who reviewed survival over the 25 years 1973 to 1997. 
 
Patient age and tumour size may best predict death from all causes and from 
metastases21 and the rate of metastases increases with size of the tumour at 
presentation27. Largest tumour diameter is currently the most widely used predictor 
of metastatic death17, 28. Prediction of metastasis can be improved if genetic and 
histological tumour characteristics are also considered. According to Damato and 












prognosis. A recent analysis of 220 choroidal and ciliary body melanomas revealed 
that monosomy 3 (Hazard Ratio 2.83) and gain of chromosome 8 (HR 3.13) are 
important prognostic factors. High percentage of monosomy 3 and gain on 
chromosome 8 strongly correlated with poor survival.37 The implication of this is that 
tissue samples from biopsies will play an increasingly important role. In addition, the 
detection of circulating malignant cells in the blood may play a future role in the 
diagnosis and management of metastatic disease30.  
 
The theory that some patients have ‘non-lethal’ tumours based on genetics and 
histology makes the generalised results of the COMS study less definitive and a more 
individualised approach to prognosis is needed. 
 
Endoresection 
High doses of radiation required to treat larger tumours result in significant ocular 
morbidity. This can be avoided if the tumour is initially resected, thus reducing the 
dose of radiation used as consolidation treatment. Tumours growing into the visual 
axis but which do not directly involve the foveal and optic disc areas are particularly 
good candidates for resection with the aim being to clear the visual axis and improve 
vision. García-Arumí and Sararols et al10 treated 25 eyes with high (>9mm thick) 
posterior choroidal melanoma with promising results although follow-up was short 
(median 31 months). Although tumours involving the ciliary body may be amenable 
to trans-scleral resection, endoresection is generally not performed on these more 












basal diameter exceeding 10mm or if more than one third of the optic disc margin is 
involved9. 
 
An additional advantage of the procedure is the availability of tumour material. 
Histological factors such as epithelioid cell type, closed loop patterns and high 
mitotic rate, and cytogenetic factors such as chromosome 3 deletions and gains on 
chromosome 8 correlate with largest tumour diameter which in turn correlates with 
metastatic death31, 37.  
 
Endoresection outcomes 
1) Visual loss 
Visual outcomes vary depending on the location of the tumour and are affected by 
complications of treatment. Retinal detachment is a significant complication 
occurring in 9.4% to 32.6% of cases and the development of cataracts attributed to 
silicone oil from 25% to 48%9, 10, 20. 
 
García-Arumí and Sararols et al10 achieved a mean of 20/100 (LogMAR 0.7)  (range 
from LogMAR 3.0 to LogMAR 0.18) in 25 eyes after 31 months and, in another 
series12, 15% achieved better than 20/200 over 70.6 months. In the series by 
Karkhaneh and Chams et al20, only 13% of 15 non-enucleated eyes were better than 
CF over 89 months although the tumours involved the fovea in 45% of cases. Kertes 
and Johnson32 achieved 6/60 or better in 31.2%. In Damato and Groenewald’s  early 
series9 of 36 non-enucleated eyes 50% were CF to 6/60 and 14% better than 6/60 















2) Tumour recurrence / local control 
Local tumour recurrence rates after endoresection vary. Seven (17%) of 41 patients 
undergoing endoresection with laser consolidation to the tumour bed had 
subsequent laser at the margin of the resection because of increased pigmentation 
although definite recurrence was not diagnosed9. Damato suggests a 10% local 
recurrence after endoresection26. Local recurrence was documented in 5.8% by 
García-Arumí and Zapata et al12. 
 
3) Globe retention (enucleation) 
In Karkhaneh and Chams series11 of 20 eyes, two eyes (10%) were enucleated 
intraoperatively due to severe haemorrhage and a further three eyes (15%) were 
enucleated over a mean follow-up of 89 months for recurrence (2 eyes) and 
development of a painful blind eye (1 eye). Seventy five percent of eyes were 
retained. Others have achieved higher retention rates of 90% over median of 20 
months9, 92.1% of 38 eyes over 70.6 months12 and 100% of 25 eyes over 31 
months10. Reasons for enucleation included blind, painful eyes, severe intraocular 
haemorrhage, tumour recurrence, patient preference, intractable retinal 















Consolidative treatment may be applied to the tumour bed following resection.
Options include plaque therapy or photocoagulation. In Damato and Groenewald’s
earlier series9, they treated the entire bed of the surgical coloboma and the margins
of the choroid with strong laser burns in an attempt to destroy any residual tumour
cells. In addition, cryotherapy was applied to the sclerotomies to destroy any tumour
cells that may have seeded to these areas. In this series and others10, if tumour
removal was uncertain a Ruthenium-106 plaque was applied to the sclera to
irradiate the tumour bed, care being taken to reduce optic nerve radiation. In the
same author’s hands it became routine practice to perform adjunctive plaque
radiotherapy after local resection after 199533 and in other centres since 200312. If
endoresection is performed in our department, it is standard treatment to
consolidate with an Iodine-125 plaque
Authors of a more recently published study11 highlight the option of endoresection
in regions of the world where radiotherapy may not be available. In the absence of
radiation services their surgical excision was consolidated with laser
photocoagulation to the scleral bed at the time of excision. . As most of the
endoresections in this study were performed by specialists outside our centre the
routine use of Iodine-125 consolidation is inconsistent. It is also important to note
that the doses of consolidation treatment with radiation (when used) are
significantly lower than plaque brachytherapy alone. Endoresection should therefore












4) Metastases / survival 
The same authors11 found a 5% mortality due to metastases at 7.5 years and local 
recurrence at the margin of the surgical coloboma in one of 20 patients (5%) over a 
similar time period.  
 
With endoresection techniques, Kertes and Johnson et al32 consolidated with tumour 
bed photocoagulation and found 9.4% (three of 32 patients) mortality due to distant 
metastases at 3.5 years. Damato and Groenewald et al9 found 2% mortality from 
metastases over 41 month follow up. In this series selected patients received 
Ruthenium-106 plaque consolidation when the tumour margins were indistinct. 
García-Arumí and Sararols et al10 also routinely applied photocoagulation to the 
scleral bed unless there were tumour remnants which could not be resected. They 
then applied a Ruthenium-106 applicator. They showed no mortality due to 
metastases after 2.5 years follow up. In a further study12 the same authors failed to 
demonstrate statistical difference in survival with the use of post-operative 
brachytherapy although the comparison may not have been reliable due to study 
design. A review from 2004 suggested that there is no current evidence that local 
resection of posterior uveal melanoma is any different from enucleation or radiation 

















Summary and interpretation of literature (not all studies are included) 
 
Table 2 summarises some of the important study findings: 
 
 
Table 2: Summary of study outcomes 
 
 Brachytherapy Endoresection 
Outcome Outcome Time Author Outcome Time Author 
Visual acuity 63%>LogMAR 1.00 5 years (22) Mean LogMAR 0.70 31 mo (10) 
 34%>LogMAR 1.00 5 years (13) 13%>LogMAR 2.00 89 mo (11)* 
 35%>LogMAR 1.00 5 years (23) 64%>LogMAR 2.00 20 mo (9) 
Recurrence 10.3% 5 years (24) 10%  (26) 
 8% 5 years (23) 5.8%  (12) 
 3.6-14.3% 3 years (6,8)    
Enucleation 12% 5 years (24) 25% 89 mo (11) 
 24.5% 39.5 mo (6) 10% 20 mo (9) 
 5-10%  (24-26) 0% 31 mo (10) 
    7.9% 70.6 mo (12) 
Survival All cause   Metastases specific   
 82% 5 years (14,21) 92.5% 5 years (20) 
 80-90% 5 years (6,23) 90.6% 3.5 years (32) 
 81.6% 5 years (2) 98% 41 mo (9) 
    100% 2.5 years (10) 
 
*45% of cases involved the macula 
 
Conclusion 
There is heterogeneity in the reporting of visual outcomes and variation in follow-up 
time which makes meaningful comparison difficult. In addition the all-cause 
mortality reported in most brachytherapy studies is not comparable to the 
metastases specific mortality rates reported in the endoresection studies. 
 
The above outcomes are based on case series and meta-analyses for the two 
treatments independently. There is a lack of comparative data of different treatment 
methods in the management of choroidal melanoma. There are significant barriers 
to the likelihood of randomised trials being performed, particularly regarding 












ocular and potentially systemic complications related to endoresection and the 
associated ethical considerations around treatment decisions. There may, however, 
be advantages to performing endoresections in certain patients particularly with 
regard to visual outcomes. Our study compares brachytherapy and endoresection 
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Selection of patients for endoresection based on tumour characteristics may result in better 
visual outcomes. We found no difference in recurrence rates, enucleation rates and 
























To report and compare the outcomes of brachytherapy and endoresection in the treatment 
of medium sized choroidal melanoma in South Africa. 
Methods 
Retrospective cohort study. Consecutive participants undergoing brachytherapy for medium
sized choroidal melanoma were compared with a cohort of participants undergoing
endoresection. Primary outcomes were final best corrected visual acuity, recurrence rates, 
enucleation rates and rates of metastases or death. Regression models were used to
examine patient and tumour characteristics for predictors of outcomes.
Results 
One hundred and sixty two brachytherapy and 25 endoresection participants were followed
for a median of 56.4 and 56.3 months respectively. Tumours undergoing endoresection were 
thicker (6.6mm vs. 4.6mm, p<0.001) and further from the fovea (5.1mm vs. 3.8mm, p=0.04).
Forty percent in each group maintained a visual acuity of 6/18 or better. The odds of poor 
visual outcome were 4.2 times higher in the brachytherapy group (p=0.046). Presenting
visual acuity, tumour thickness and distance from the fovea were associated with poor visual 
outcomes. Recurrence rates, enucleation rates and metastases or death were similar in each 
group. Recurrence was more likely with lesions closer to the optic disc. Risk of enucleation
increased with tumour thickness (p=0.033). Tumour thickness may be associated with
increased risk of metastases or death (p=0.09). 
Conclusion 
Endoresection may offer patients with medium sized choroidal melanoma better visual 












Conservative management of choroidal melanoma aims to effectively treat the tumour, 
preserve the globe, and retain visual function if possible. Brachytherapy1-3, charged particle 
irradiation4 and surgical excision5-8 are all well described. Plaque brachytherapy is the most 
commonly used treatment and is supported by the results of the Collaborative Ocular 
Melanoma study (COMS) which showed no increase in mortality comparing brachytherapy 
with enucleation9. Endoresection was described in 198610 and a number of series have been 
published5-7, 11.  
The main causes of visual loss among brachytherapy patients are cataract and radiation
maculopathy. Patients undergoing endoresection often undergo lens extraction at the time 
of surgery but may suffer severe intraoperative haemorrhage or postoperative retinal
detachment. Adjunctive radiotherapy used in these patients is of lower dose as only the
tumour base is treated which may help to limit radiation related visual loss. Although visual 
loss is common with both treatment methods, there is no current evidence that
brachytherapy has favourable outcomes compared to endoresection and no randomised 
trials have been performed. 
Patients are treated by both techniques in South Africa. Groote Schuur Hospital is the only 
centre to provide brachytherapy for the treatment of uveal melanoma. Patients are referred 
from private and public facilities throughout the country as well as from neighbouring 
countries. A database has been in place since Iodine-125 brachytherapy was pioneered in 
the 1970’s but few results have been published12. Endoresection is performed in a number 











In this study we examine and compare the outcomes of patients undergoing brachytherapy 
for choroidal melanoma at Groote Schuur Hospital and patients undergoing endoresection 
from a national database.  
Patients and Methods 
We conducted a retrospective cohort study comparing two groups of participants, one
undergoing brachytherapy and the other endoresection for the treatment of medium sized 
choroidal melanoma. The brachytherapy group was sourced from the database of choroidal 
melanoma patients collected by the department of Radiation Oncology at Groote Schuur
Hospital. Exclusion criteria included tumours that extend into the ciliary body, tumours more
than 10mm in height and / or 16mm in widest basal diameter and patients with less than 6 
months follow-up. Treated patients were followed up by their referring ophthalmologists. 
Follow-up data were obtained from these ophthalmologists from whom six monthly clinical
updates were routinely requested.
Endoresections are performed by a small group of vitreo-retinal surgeons in the country.
Specific email notification was sent to five surgeons with known experience in this procedure 
informing them of the proposed data collection and requesting their contribution to the
database. Four of the five responded (see appendix B) and submitted information on all
endoresections they had performed. All data were entered into a standardised database
designed for the study which had been sent to each participating surgeon. In addition, all
other members of the South African Vitreo-Retinal Society (SAVRS) were contacted via the
society email list or telephone inviting participation in the study. No other retinal surgeons 
had experience with endoresections. Analysis was restricted to those patients receiving
endoresection as the primary treatment of the melanoma. Tumour characteristics and











Baseline observations included date of birth, gender, date of diagnosis, left or right eye, pre-
operative visual acuity, presence of other non-associated pathology and type and date of the 
procedure performed. The documented preoperative tumour characteristics were height 
(thickness), largest basal diameter, distance from the optic disc and fovea, location within 
the eye (predominant quadrant), and the presence or absence of an associated exudative 
retinal detachment. 
Follow-up data included final best corrected visual acuity and any complications related to
the tumour or treatment. Tumour recurrence, enucleation of the globe, presence of
metastases and death from all causes were outcomes of interest. Snellen acuity and decimal
acuity were converted to the logarithm of the minimal angle of resolution (LogMAR acuity)
for analysis. Light perception and no light perception outcomes were not included in the
calculation of mean visual acuity but were assigned a LogMAR of 5.0 for categorical 
analysis13. Recurrence of tumour growth was made on the basis of clinical examination and
ultrasound measurements or confirmed on histology in enucleated eyes. Diagnosis of
metastases was usually made on ultrasound of the liver and confirmed by an oncologist.
Statistical analysis was done using STATA 11.0 (StataCorp. LP, USA). A logistic regression
model was used to estimate prognostic factors for poor visual outcome. The Kaplan-Meier
method was used to analyse survival proportion until recurrence, enucleation and
metastases or death from all causes. Cox regression analysis was used to estimate prognostic













1) Participants excluded from analysis 
Participants were excluded from the analysis for the following reasons: Seven of the 41 
patients in the endoresection group and four of the 249 in the brachytherapy group had 
large tumour characteristics despite being classified as medium size. Eight endoresections 
had been performed as secondary treatment. Follow-up information was not available for 
one patient in the endoresection group and 29 patients in the brachytherapy group. At least 
six months follow-up data were available on 25 patients undergoing primary endoresection 
and 210 patients undergoing brachytherapy. It was discovered that prior to 1st May 1994, 
while brachytherapy was still being developed, a sub therapeutic dose was being 
administered. The 48 participants treated prior to that date were therefore excluded from 
the analysis (see Figure 1). (These participants are analysed in Appendix G). 













The mean age at diagnosis, gender, laterality (left or right eye), presence of exudative retinal 
detachment and baseline visual acuity were similar in each group. The baseline 
characteristics of each group are summarised in Table 1. The tumours undergoing 
endoresection were significantly thicker than those receiving brachytherapy (mean of 
6.6mm vs. 4.6mm. P <0.001) and the mean distance from the fovea was greater in the 
endoresection group (5.1mm vs. 3.8mm. p=0.04). About 70% of patients in both groups had 
6/18 or better Snellen acuity at the time of diagnosis. 






Age at diagnosis (median) 56.5 59.1 0.27 
Gender 15 Male 10 Female 73 Male 89 Female 0.16 
Laterality 13 Right 12 Left 83 Right 79 Left 0.94 





Category at diagnosis (%) 
1  
Snellen 6/5 to 6/18 
LogMAR -0.08 to 0.48 
19 (76.0) 111 (68.5) 
0.43 
2 
Snellen 6/24 to 6/48
LogMAR 0.60 to 0.90
0 (0.0) 12 (7.4) 
3  
Snellen 6/60 to 3/60 
logMAR 1.00 to 1.30 
1 (4.0) 16 (9.9) 
4 
2/60 or worse 
LogMAR 1.48 or worse 
5 (20) 23 (14.2) 
Tumour characteristics 
Height (mean) 6.6mm 4.6mm < 0.001 
Maximum basal diameter (mean) 11.0mm 10.0mm 0.07 
Temporal or posterior pole 15/25 (60%) 92/162 (56.8%) 0.76 
Distance to disc 
(mean) 
4.2mm 4.6mm 0.79 
Distance to fovea 
(mean) 
5.1mm 3.8mm 0.04 
Exudative Retinal Detachment 12/21 (57.1%) 62/161 (38.5) 0.16 
Follow-up (median months) 56.3 56.4 0.78 














The median follow-up was almost identical at 56.3 months in the endoresection group and 
56.4 months in the brachytherapy group (p=0.78). 
 
3) Final visual acuity 
Final visual acuity was available in 156 brachytherapy patients and all 25 endoresection 
patients. About 40% of both groups retained vision of 6/18 or better at the end of follow-up. 
Nine out of 25 (36%) endoresection and 70 out of 156 (45%) brachytherapy patients had 
2/60 or worse at the last visit. We found that the odds of a poor visual outcome (visual 
acuity less than 2/60) was 4.2 times higher in the brachytherapy group compared to the 
endoresection group (p=0.046) when controlled for presenting visual acuity and tumour 
characteristics. The outcomes are summarised in Table 2. 
 
Table 2: Outcomes 
Visual outcome Endoresection (n=25) Brachytherapy (n=156) P - value 
Final visual acuity (mean)  0.87 





Snellen 6/5 to 6/18 
LogMAR -0.08 to 0.48 








Snellen 6/24 to 6/48 
LogMAR 0.60 to 0.90 
5 (20%) 16 (10.3%) 
3  
Snellen 6/60 to 3/60 
logMAR 1.00 to 1.30 
1 (4%) 9 (5.8%) 
4 
2/60 or worse 
LogMAR 1.48 or worse 
9 (36%) 70 (45.2%) 
Other outcomes Endoresection (n=25) Brachytherapy (n=162) P - value 
Recurrence 5 (20%) 23 (14.2%) 0.54 
Enucleation 2 (8%) 16 (9.9%) 1.00 
Metastases or death 5 (20%) 21 (13.0%) 0.35 
 
 
Of the non-enucleated eyes that retained better than PL vision (21 in the endoresection 











(Snellen acuity 6/48) in the endoresection group and LogMAR 1.03 (Snellen acuity 6/60) in 
the brachytherapy group (p=0.76). 
Poor visual outcome (2/60 or worse) was associated with poorer visual acuity at 
presentation, increase in tumour height and smaller distance to the fovea. Participants 
presenting with visual acuity of 6/60 were 1.9 times more likely to experience poor outcome 
than those presenting with normal vision (p=0.03). Each 1mm increase in height was 
associated with 43% increase odds of poor visual outcome (p=0.006) and each millimetre 
further from the fovea was associated with 32% reduction in odds of a poor visual outcome 
(p=0.006). (The final logistic regression model can be seen in Appendix H.) 
4) Rates of recurrence, enucleation, metastases or death
We found no difference in the rates of recurrence (20% vs. 14.2%, (p=0.55), enucleation (8%
vs. 9.9%, p=1.00) or metastases / death (20% vs. 13%, p=0.35) between the endoresection
and brachytherapy groups respectively (see Table 2).
Survival times to recurrence, enucleation and metastases or death are shown in Figure 2.
Figure 2. Survival analysis
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Figure 2. Survival analysis (continued) 
 
Metastases or death survival curves  (p=0.32) 
 
 
Seventy five percent of the brachytherapy group had no recurrence by 130.6 months and 
75% of the endoresection and brachytherapy groups had no metastases or death until 97 
and 156 months respectively. There was no difference in survival curve estimates of time to 
recurrence (p=0.89), time to enucleation (p=0.72) or time to metastases or death from any 
cause (p=0.32) between the treatment groups.   
 
Cox regression modelling (See Appendix H) revealed that for each millimetre further from 
the optic disc the hazard of recurrence was reduced by 31% (p=0.016). Age at diagnosis, 
lesion height and widest diameter were not associated with risk of recurrence. Increase in 
tumour thickness was associated with increased risk of enucleation (p=0.033). Each year of 
increased age at presentation was associated with an 8.6% increased risk of metastases or 
death from any cause during the follow-up period (p<0.001). Our data suggest that tumour 
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While a number of globe sparing treatments are available in the management of choroidal 
melanoma there are no randomised trials comparing brachytherapy and endoresection. 
Because of the low incidence of choroidal melanoma, the individuality of tumour 
characteristics and higher risk of complications associated with endoresections it is unlikely 
that such studies will be undertaken. We have compared two cohorts of patients undergoing 
these procedures in an attempt to identify potential benefits.   
We found good visual outcomes (LogMAR < 0.48) in a similar proportion (40%) of each group 
However, the odds of poor visual outcome (LogMAR > 1.48) was 4.2 times greater in the 
brachytherapy group (p=0.046). Our study agrees with other larger series that good 
presenting vision, tumour thickness and greater distances from vital structures (optic disc 
and fovea) are correlated with visual outcomes2, 14. 
Loss of vision is a common and expected complication of both brachytherapy and
endoresection. Forty five percent of the COMS patients had visual acuity of LogMAR 1.60 or
worse at 5 years1. We found a similar outcome (LogMAR >1.48 in 45.2% at a mean of 59 
months) among brachytherapy patients although our data represent a mean visual acuity
with outcomes from 6 months to nearly 15 years. Visual results following endoresection vary
with few series achieving good outcomes. Vision better than 6/60 (LogMAR 1.00) has been
achieved in 14% - 31%5, 7, 15. One series of 25 eyes6 performed on particularly tall tumours,
none of which involved the macula, achieved a mean of 6/30 (LogMAR 0.7) after 31 months.
In our study the mean tumour thickness was significantly higher (6.6mm vs. 4.6mm) and the
tumour base significantly further (5.1mm vs. 3.8mm) from the fovea at baseline in the 
endoresection group. This selection of patients into the endoresection group may explain
better visual results than other series and supports the findings of García-Arumí and Sararols 











Treating tall tumours with radiation delivers a high global dose to achieve therapeutic levels
at the tumour apex. This increases the risk of poor visual outcomes. In these instances it is 
advantageous to remove the bulk of the tumour and apply a lower dose of radiation or laser
to the tumour bed. Despite early recommendations5 to resect tumours close to the optic
disc, endoresection may be considered in those where the tumour base is further from vital
posterior structures. Tall tumours invading the visual axis with a small base away from the
posterior pole may therefore be the ideal cases to experience visual benefit of
endoresection. As we only analysed final visual acuity we were unable to demonstrate
trends of visual loss. One might expect a time related loss of vision among brachytherapy
patients due to cataract formation and radiation maculopathy but a more dramatic initial
reduction in endoresection patients (as a result of surgery) followed by stabilisation.
Tumour recurrence following brachytherapy varies between 3.6% and 14.3%3, 16, 17. The
COMS showed a recurrence rate of 10.3% (CI 8.0% – 13.2%) at 5 years18. We found a
recurrence rate of 14.2% at a median follow up of 59.1 months. Rates of recurrence
following endoresection vary from 5.8%7 and up to 10%19. Five out of 25 (20%) of our
patients experienced clinical recurrence which was higher than other reports. The likelihood
of recurrence following endoresection may be significantly influenced by the concurrent use
of brachytherapy or laser therapy to the sclera bed following resection. In our study only
three patients received plaque brachytherapy alone following endoresection. Twenty
received laser alone and one patient received laser and brachytherapy. Four of the 5
recurrences following endoresection had not received concurrent brachytherapy. Three of
these recurred despite laser to the tumour bed. Others have found recurrence of 3% to 5%
following laser consolidation alone11, 15. It has become increasingly common to consolidate












hospital. Our study found that recurrence was more likely with lesions closer to the optic 
disc (p=0.016) but was underpowered to demonstrate a statistical difference between 
recurrence rates in patients receiving endoresection (with or without consolidation) and 
brachytherapy. 
 
Enucleation rates following brachytherapy vary between 5% and 25%16, 18, 19, 21. The COMS 
found a 12.5% enucleation rate at five years. Series of endoresected patients report globe 
retention of 75% over 89 months22, 92% over 70.6 months7 and 100% over 31 months6. We 
found enucleation rates of 8% in the endoresection group and 10% in the brachytherapy 
group (p=1.00). Similar to other studies14 we found that risk of enucleation increased with 
tumour thickness (p=0.033) but we did not find an association with tumour diameter and 
proximity to the disc or fovea.  
 
Five year survival following brachytherapy is estimated at around 82%9, 23, 24 and has 
remained similar over the past 35 years25. Small series of endoresections looked at 
metastases related mortality (not all cause) and found rates between 0% over two and a half 
years6and 9.4% over three and a half years15. We found an all cause mortality of 13% and 
20% in the brachytherapy and endoresection groups respectively (p=0.35). Our findings 
agree with others that age (p<0.001) and possibly tumour thickness (p=0.09) best predict 
death from all causes and metastases9. Largest tumour diameter if often used as a predictor 
of metastatic disease26, 27 but we could not corroborate this finding. It is now thought that 
histological and genetic features of tumours are increasingly important in determining 
prognosis28. The implication of this is that increasing numbers of tumours are likely to 














The study of rare conditions such as choroidal melanoma is difficult, particularly when 
randomised trials are unlikely to be performed. Our study attempts to compare two cohorts 
of patients but has limitations. 3.8% of the endoresection group and 15.2% of the 
brachytherapy group were lost to follow-up. While those who were lost were significantly 
older (65.3 vs 58.0 years, p=0.005) this was not differential with respect to procedure 
performed and is unlikely to represent bias. Small numbers in the endoresection group 
significantly under power the statistical comparison of the groups. Selection of patients with 
thicker tumours further from the fovea into the endoresection group is present at baseline. 
The more favourable visual outcomes in the endoresection group may suggest that there is 
benefit in this procedure for patients with these tumour characteristics, and therefore 
provides an important finding.  
 
Visual preservation where possible is an important consideration in the management of 
choroidal melanoma. We would recommend considering endoresection in patients with 
medium sized choroidal melanoma if tumours are tall and more than 5mm from the fovea. 
Further studies are needed in this area.  
 
References 
(1) Melia BM, Abramson DH, Albert DM et al. Collaborative ocular melanoma study (COMS) 
randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 
years COMS report no. 16. Ophthalmology 2001 02;108(2):348-366.  
(2) Shields CL, Shields JA, Cater J et al. Plaque radiotherapy for uveal melanoma: long-term visual 
outcome in 1106 consecutive patients. Arch Ophthalmol 2000 09;118(9):1219-1228.  
(3) van Ginderdeuren R, van Limbergen E, Spileers W. 18 Years' Experience with High Dose Rate 
Strontium-90 Brachytherapy of Small to Medium Sized Posterior Uveal Melanoma. Br J Ophthalmol 
2005 10;89(10):1306-1310.  
(4) Gragoudas ES, Seddon JM, Egan K et al. Long-term results of proton beam irradiated uveal 
melanomas. Ophthalmology 1987 04;94(4):349-353.  
(5) Damato B, Groenewald C, McGalliard J, Wong D. Endoresection of choroidal melanoma. Br J 












(6) García-Arumí J, Sararols L, Martinez V, Corcostegui B. Vitreoretinal surgery and endoresection in 
high posterior choroidal melanomas. Retina 2001;21(5):445-452.  
(7) García-Arumí J, Zapata MA, Balaguer O et al. Endoresection in high posterior choroidal 
melanomas: long-term outcome. Br J Ophthalmol 2008 08;92(8):1040-1045.  
(8) Damato BE, Paul J, Foulds WS. Predictive factors of visual outcome after local resection of 
choroidal melanoma. Br J Ophthalmol 1993 10;77(10):616-623.  
(9) Diener-West M, Earle JD, Fine SL et al. The COMS randomized trial of iodine 125 brachytherapy 
for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 2001 
07;119(7):969-982.  
(10) Peyman GA, Cohen SB. Ab interno resection of uveal melanoma. Int Ophthalmol 1986 
04;9(1):29-36.  
(11) Karkhaneh R, Chams H, Amoli FA et al. Long-term surgical outcome of posterior choroidal 
melanoma treated by endoresection. Retina 2007 09;27(7):908-914.  
(12) Hill JC, Sealy R, Shackleton D et al. Improved iodine-125 plaque design in the treatment of 
choroidal malignant melanoma. Br J Ophthalmol 1992 02;76(2):91-94.  
(13) Holladay JT. Proper method for calculating average visual acuity. J Refract Surg 1997 
1997;13(4):388-391.  
(14) Wright PK, Damato BE. Auditing outcomes after treatment of Scottish patients with uveal 
melanoma in Liverpool. J R Coll Surg Edinb 1999 08;44(4):260-264.  
(15) Kertes PJ, Johnson JC, Peyman GA. Internal resection of posterior uveal melanomas. Br J 
Ophthalmol 1998 10;82(10):1147-1153.  
(16) Sia S, Harper C, McAllister I, Perry A. Iodine-I25 episcleral plaque therapy in uveal melanoma. 
Clin Experiment Ophthalmol 2000 12;28(6):409-413.  
(17) Krohn J, Monge OR, Skorpen TN et al Posterior uveal melanoma treated with I-125 
brachytherapy or primary enucleation. Eye (Lond) 2008 11;22(11):1398-1403.  
(18) Jampol LM, Moy CS, Murray TG et al. The COMS randomized trial of iodine 125 brachytherapy 
for choroidal melanoma: IV. Local treatment failure and enucleation in the first 5 years after 
brachytherapy. COMS report no. 19. Ophthalmology 2002 12;109(12):2197-2206.  
(19) Damato B. Developments in the management of uveal melanoma. Clin Experiment Ophthalmol 
2004 12;32(6):639-647.  
(20) Damato B, Lecuona K. Conservation of eyes with choroidal melanoma by a multimodality 
approach to treatment: an audit of 1632 patients. Ophthalmology 2004 05;111(5):977-983.  
(21) Shields CL, Shields JA, Karlsson U et al. Reasons for enucleation after plaque radiotherapy for 
posterior uveal melanoma. Clinical findings. Ophthalmology 1989 06;96(6):919-923.  
(22) Karkhaneh R, Chams H, Amoli FA et al. Long-term surgical outcome of posterior choroidal 











(23) Seregard S. Long-term survival after ruthenium plaque radiotherapy for uveal melanoma. A
meta-analysis of studies including 1,066 patients. Acta Ophthalmol Scand 1999 08;77(4):414-417.
(24) Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival.
Ophthalmology 2011 09;118(9):1881-1885.
(25) Singh AD, Topham A. Survival rates with uveal melanoma in the United States: 1973-1997.
Ophthalmology 2003 05;110(5):962-965.
(26) Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal
melanoma. Invest Ophthalmol Vis Sci 2003 11;44(11):4651-4659.
(27) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-
year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol 2006
12;124(12):1684-1693.











L NI\. ERSI IY OF J\PE T-O\\N
Hc,lrh Sci€rces Ftllty
R€sear.L Erhics Commiles
Roon Est24 Grcoit ScLuur Hospit l Ord Miin Buildi.g
Obsctra.ory ?925
Telephone [Ozr] lnc !333 ..F,6imile [02r] $6 6111
e  b . r :  h n . . \ c n F d ( 3 u ( { 7 1
REC REF: 391/2008
PRO:|OCOL: ENDORESECfION FOR CHOROIDAI MELANOMA -{ RElr'IEW OI
PATIENIS TREAIED TN SOUTH AFRICA
'l}ant 
t.u for subniting you sody to tbe Resaclr Ethics Comhit.e for reus
It is a tlcrm ro inlom fou i\ai ihe Ethids Cominee hs foErrry approv€d the 1bo!._m.ntioocd studv
Aplrd.I is gidied for olc y€d till tL€ 15d SeDtmber 200r)-
trlese submit an 'mu,l pogr.$ ieport il the resetcb coniinus belond th. dpirv d*e Plcde subrii x Incf
subn,ry of findings if you cohPlcte the study vithin th. 4Prov,l Penod so thr ve lI closc ou Elc
llL.s. notc th.r L\e ongoitg ctAic,l conduc of rbc study retuiG the mPodibiliq of rhe Pri'dpal
Pleas. quot the REC. REF i! all you conespold.lce.
lk',/tX
DPCHAIRPERSON. HS! HUM{N E THICS
Iidcnl \r{'idc Asuncc NMbei: !w400001637
Insiotionrl Rdnd Bo,!d (lRB) f,umb.i IR!00001933
UNIV ::;ITY  CAPE O\X'  
08 ~plcmbet 2008 
REC : 391/2008 
Dr Jamcs Ricc 
Opbthahnology 
Dcu Dr Rice 
• 
ealth eD u Faculty 
Ruearch t iCi ttee 
m £52-24 OOle h ospilal l r.biD uilding 
elValOr 7  
phone (021]406 63 8 • Facsimile (021]406 41 1 
-mai l: larnr;e$.cmjcdi@Uct.ac.7.a 
T : S TION  l L NO A A V F 
PATIENTS TED I    
'nunk )'OU for submitting r sru  10 the <:$CUCh l i s m ncc  u.icw, 
II j, a pl""sUtt to inform )'OU tho! t  t ics om ill~~ l$ rmally pprovcd ~ .bo\·~,""' t n~d tudy 
Approv.I is ranl~d f r ne ear liU he IS" cple 009, 
I'IC:l1.C submit an annual ro ress r ort f e csat<:h CO t ue  c)'  e expiry ollt , leasc lubm t I hrief 
summary of findings if ou mplete t c Study with e app=.,.] period so at w CI.Il lose w 6Je. 
1'1""I.C note that the ngoin  ethical onduct the rudy nWns e resp nsibility the princi l 
;n\'C$!igalor, 
Plcase qUOle the , ;II aU r COrte lldellce. 
Yours sincerely 
~~L~ Dr CHAIRPERSON. F AN T  
Fedcnl Wide ;'nunfKe umber. 1'\1;1;.0 0163 , 











Rom E5Z-24 Groor. khuur H6piEl Old Mai. Buildins
r€lephohe {02! a.5 €626 r F.dinire t0211a06 au
. €-mall: koee efliedi@ !.i{ -
Thank vou for submiti4 your letter to
ApproElissEntedtoraturtherlzdornhsuntlllslanuary2012.Tl stppdvalincludesth€amendnefttoadda
second ataba* in ihe analysit
Pleae submit ao annral pos€s €pod It the sludy continues beyond the approGl p€nod.
Plea* note lhat the oGoing ethlel condu.i of the studv emai6 rhe responsibilltv ot the p'incipal inve5tisator'
Pl€a* quab the iEc. REF in .fl Yo
CHOROIOAL METANOMA A REVIEW
tne facult of Herhh s.ien.es lluman Reeat h Eihics conmit€e dared
ut4":1kt,rclLy
UNIVERSITY Of CAPE TOWN 
10 Janllilry 2011 
HREC REF: 391/2008 
Or JC Rice 
Ophthalmology 
H53.0MB 
Dear Dr Rice 
• 
faculty f H alth SCiences 
Human Re~earch Ethics Committee 
oo  S2-24 roote Schuur os ta ld in uilding 
Observatory 792S 
Tel one [021]406 6 26 • acsimile {021] 406 6411 
e-mail : lim es.emjedi@uCl.aUiI 
PROJECT TITLE: ENOORESECTION FOR HOROIDAL LANOMA EVIEW OF PATIENTS TREATED IN SOUTH 
AFRICA 
Thank you for submitting r letter to the Faculty of alt  Scie ces Hu  es rc  t ics C mmitt e ted 
21 December 2010. 
pproval is granted for a further 12 months until IS January 2012. Thi  a ro l ludes the amendme t to add a 
second atabase i  t  nalysis. 
Please submit an nnu l rogress report if t  st y nti es yond  pproval eri d. 
Please note that the ongoing ethical conduct of the study re ins t  r sponsibility f  r i l e:rtigator. 
Please ote t  REt. EF I  all your correspondence. 
You.s since rely 
VN1.'1 1121 Lffiy 












Invitation to participate 
Surgeons known to perform endoresection for choroidal melanoma in South Africa: 
Dr. Raoul Scholtz 
Melrose House 
14 Palmyra Road 
Claremont 7708  
Cape Town 
Dr. Kelvin Rivett 
18 St. James Road 
Southernwood 5201 
East London 
Letter of invitation to other members of the South African Vitreoretinal Society
Dear members of the SAVRS
I am performing a study comparing brachytherapy and endoresection for choroidal melanoma and I
am putting together a national database of endoresection data from all those who perform the
procedure.
Hence I would like to extend an invitation to all colleagues who have performed endoresection at any 
time to participate in the study. I hope that we will publish the data in a paper as the Choroidal
Melanoma Endoresection Study Group with full acknowledgment of all contributors.
I hope to minimise demands on your time by producing tables and making data collection as easy as
possible.
Please would you let me know by return email to james.rice@uct.ac.za if you are willing to participate
I would be most grateful.
Kind regards 
James Rice  
Groote Schuur Hospital 
Cape Town 
Dr. Louis Kruger  
22 Hocky Avenue 
Northcliff 2195 
Johannesburg 
Dr. Robert Nutt 



















Date of birth 
Gender  
Eye (left or right) 
 
Preoperative data 
 Date of diagnosis 
Confirm absence of systemic metastases on liver ultrasound, chest X ray, liver function tests 
Reason not for primary brachytherapy / for selecting endoresection  
Best corrected pre-operative visual acuity 
 Non-associated ocular pathology 
Tumour characteristics 
Prior treatment 
Location (predominant quadrant) 
Height (mm) 
Widest diameter (mm) 
Distance to disc (mm) 
Distance to fovea (mm) 
Surgery (endoresection or brachytherapy) 
 Date of surgery 
Endoresection technique used 
 Intra-operative events 
 Consolidation treatment 
 Yes / No 
 Plaque or laser 
Second procedures performed later  
Late complications  
Pathology 
 Cell type 
Genetics (if available) 
 
Post-operative data  
Final BCVA 
Date of last visit 
 Presence of local recurrence  
 Date diagnosed 
Enucleation  
Yes / No  
Date of enucleation  
Reason for enucleation  
 Presence of metastases 
Date diagnosed 
 Date of death 
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references. The format for all submitted manuscripts is basically as described above with a few exceptions. 
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Participant selection and data quality 
 
Choroidal melanoma is a condition that predominantly affects Caucasians. As many 
Caucasians in South Africa are of European descent it is likely that our results are 
comparable to other international study populations and not unique to an ‘African’ 
population. Given that Caucasians historically have had better access to medical care in 
South Africa it is likely that the participants undergoing endoresection and brachytherapy 
are representative of a similar source population.  
 
The method of data collection and thus quality of data in each group was similar. Although 
baseline characteristics were collected and maintained in a central database in the 
brachytherapy group and collected from individual surgeons in the endoresection group 
there is no reason to believe that there should be a difference in baseline data quality. 
Similarly, all follow up data were collected in a similar method for both groups as all 
participants were followed up by suitably qualified ophthalmologists from around the 
country. 
 
Most data are quantitative and specific and unlikely to be systematically different between 
the groups. Although early tumour recurrence is sometimes difficult to diagnose we have no 
reason to believe that there should be a difference in the clinical diagnosis of recurrence 
between the groups. We have already discussed the selection into the endoresection group 
of taller tumours further from vital structures within the eye. The reason for the difference 
in visual outcomes may be related to this selection bias highlighting the possible benefit of 














Given the potential for more anaesthetic complications related to endoresection in older 
patients we might have expected selection of younger patients into the endoresection group 
but we found similar median ages in both groups. 
 
Lack of randomisation to treatment arms, however, and certain tumour characteristics (e.g. 
tumour thickness) favouring selection for endoresection (selection bias) reduced the 
counterfactual comparison of the groups. There was also insufficient power to detect 

























Appendix F:   
Loss to follow up 
 
Loss to follow up data are summarised in the tables A and B below: 
 










Loss to follow up of 30 participants (29 brachytherapy and 1 endoresection) reduced the 
precision of our estimates but was not significantly different between treatment groups 
(p=0.14). Baseline characteristics of the two groups are shown in Table B. Due to the small 
number of endoresections it is difficult to draw conclusions regarding the significantly older 
age of those lost to follow up (65.3 years vs. 58 years, p=0.005). Because the differential loss 
to follow up is only present with respect to this risk factor and not with respect to procedure 
this may not represent bias. Similarly the possible difference in widest diameter (10.5mm vs. 















Loss to follow up Endoresection Brachytherapy Total 
No 25 162 187 
Yes 1 29 30 

















Table B: Baseline characteristics 
 
Variable Follow-up 
(n = 187) 
Loss to follow-up 
(n=30) 
p-value 
Age at diagnosis (mean) 58.0 65.3 0.005 
Gender 88 Male 99 Female 13 Male 17 Female 0.84 
Laterality 96 Right 91 Left 14 Right 16 Left 0.70 
Presenting Visual Acuity (mean) 0.61 0.60 0.27 
Category at diagnosis (%)    
1  
Snellen 6/5 to 6/18 
LogMAR -0.08 to 0.48 







Snellen 6/24 to 6/48 
LogMAR 0.60 to 0.90 
12 (6.4) 4 (13.3) 
3  
Snellen 6/60 to 3/60 
logMAR 1.00 to 1.30 
17 (9.1) 4 (13.3) 
4 
2/60 or worse 
LogMAR 1.48 or worse 
28 (15.0) 3 (10.0) 
Tumour characteristics    
Height (mean) 4.9mm 5.1mm 0.65 
Maximum basal diameter (mean) 10.1mm 10.5mm 0.10 
Temporal or posterior pole 107 (57.2%) 14 (46.7%) 0.28 
Distance to disc  
(mean) 
4.5mm 3.9mm 0.51 
Distance to fovea 
(mean) 
4.0mm 3.2mm 0.23 















Subgroup analysis of brachytherapy procedures done before 1st May 1994 
 
Table A: Baseline characteristics of patients treated before and after 1st May 1994 
 
Prior to 1994 the department of Radiation Oncology designed and manufactured 
brachytherapy devices based on laboratory based dosing models. Following international 
discussion it was decided that the radiation doses used in all brachytherapy patients prior to 
that date were sub therapeutic. All subsequent patients received a dose of 80Gy to the 
tumour apex in keeping with internationally accepted guidelines. This analysis compares the 
baseline characteristics and outcomes of the early plaque cohort with those treated after 1st 
May 1994. 
Variable Early plaque 
Before 1st May 1994 
(n=45) 
Later plaque 
After 1st May 1994 
(n=187) 
P - value 
Age at diagnosis (median) 54.2 58.0 0.11 
Gender 20 Male 25 Female 88 Male 99 Female 0.75 
Laterality 22 Right 23 Left 96 Right 91 Left 0.77 





Category at diagnosis (%)    
1  
Snellen 6/5 to 6/18 
LogMAR -0.08 to 0.48 







Snellen 6/24 to 6/48 
LogMAR 0.60 to 0.90 
5 (11.1) 12 (6.4) 
3  
Snellen 6/60 to 3/60 
logMAR 1.00 to 1.30 
2 (4.4) 17 (9.1) 
4 
2/60 or worse 
LogMAR 1.48 or worse 
5 (11.1) 28 (15.0) 
Tumour characteristics    
Height (mean) 5.2mm 4.9mm 0.15 
Maximum basal diameter (mean) 12.1mm 10.1mm <0.001 
Temporal or posterior pole 21/45 (46.7%) 107/187 (57.2%) 0.20 
Distance to disc  
(mean) 
3.1mm 4.5mm 0.01 
Distance to fovea 
(mean) 
2.9mm 4.0mm 0.23 
Exudative Retinal Detachment 20/45 (44.4%) 74/182 (40.7) 0.74 
Follow-up (median months) 96.5 56.3 <0.001 


















Maximum basal diameter was greater (p<0.001) and proximity to the optic disc was closer 
(p=0.01) in the early treatment group. Outcomes by early and late treatment are shown in 
Table B:  
 
Table B: Outcomes 
 
 Early plaque 
Before 1st May 1994 
(n=45) 
Later plaque 
After 1st May 1994 
(n=162) 
P - value 






Snellen 6/5 to 6/18 
LogMAR -0.08 to 0.48 








Snellen 6/24 to 6/48 
LogMAR 0.60 to 0.90 
3 (7.1%) 16 (10.3%) 
3  
Snellen 6/60 to 3/60 
logMAR 1.00 to 1.30 
3 (7.1%) 9 (5.8%) 
4 
2/60 or worse 
LogMAR 1.48 or worse 
30 (71.4%) 70 (45.2%) 
    
Recurrence 15 (33.3%) 23 (14.2%) 0.008 
Enucleation 13 (28.9%) 16 (9.9%) 0.003 
Metastases or death 10 (22.2%) 21 (13.0%) 0.16 
  
 
Final visual acuity, categorical visual outcomes, recurrence rates and enucleation rates were 
all significantly worse than those treated with therapeutic doses. Logistic regression models 
examining the prognostic factors for poor visual outcome of all brachytherapy patients 
revealed that early (sub therapeutic) plaque treatment was 3 times more likely to result in a 
poor visual outcome (p=0.018), 2.5 times more likely to result in recurrence (p=0.041), 2.9 
times more likely to require enucleation (p=0.037) . These results are not surprising and 












Appendix H:  
Regression analysis 
Logistic regression models for predictors of outcomes 
Logistic regression for poor visual outcome if treated after 1
st
 May 1994 
Prediction variable Odds ratio p-value 95% Confidence Interval 
Vision at diagnosis 1.89 0.03 1.06 3.36 
1mm increase in 
tumour height 
1.43 0.006 1.11 1.85 
1mm increase in 
distance from 
fovea 
0.69 0.006 0.53 0.90 
Logistic regression analysis for patients treated  prior to 1
st
 May 1994 (early plaque as prediction 
variable) 
Outcome Odds ratio p-value 95% Confidence Interval
Poor vision 2.98 0.018 1.21 7.35 
Tumour 
recurrence 
2.46 0.041 1.04 5.86 
Enucleation 2.86 0.037 1.06 7.69 
Cox models for predictors of outcomes
Final Cox regression model for recurrence as outcome
Prediction variable Hazard ratio p-value 95% Confidence Interval 
1mm increase in 
distance from disc 
0.69 0.016 0.51 0.93 
Final Cox regression model for enucleation as outcome
Prediction variable Hazard ratio p-value 95% Confidence Interval 
1mm increase in 
tumour height 
1.46 0.033 1.03 2.06 
Final Cox regression model for metastases or death as outcome 
Prediction variable Hazard ratio p-value 95% Confidence Interval 
Age at diagnosis 1.09 <0.001 1.05 1.23 
1mm increase in 
tumour height 
1.22 0.09 0.96 1.55 
